Overtoom Hidde C G, Eyck Ben M, van der Wilk Berend J, Noordman Bo J, van der Sluis Pieter C, Wijnhoven Bas P L, van Lanschot J Jan B, Lagarde Sjoerd M
Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Ann Surg. 2024 Aug 13. doi: 10.1097/SLA.0000000000006488.
To investigate whether prolonged time to surgery negatively affects survival, pathological outcome or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy for locally advanced esophageal cancer.
Historically, the standard time to surgery (TTS) has been six to eight weeks after completion of nCRT. The effect of prolonged TTS is gaining interest, with contradicting results on survival and surgical morbidity. It can be hypothesized that, in patients with residual disease six weeks after completion of nCRT, prolonged TTS might be associated with worse survival and higher morbidity.
Patients with locally advanced esophageal cancer who had biopsy-proven residual disease six weeks after nCRT and underwent surgery, were categorized according to interval to surgery (TTS>12w vs. TTS≤12w). Primary outcome of this study was overall survival. Secondary outcomes were disease-free survival, surgical outcomes, pathological outcomes, and postoperative complications. Multivariable Cox regression was used for comparing survival and logistic regression for other outcomes, adjusted for the confounders age, cT, cN, Charlson comorbidity index, weight loss during nCRT, and WHO performance score after completion of nCRT.
Forty patients were included for TTS>12w and 127 for TTS≤12w. TTS>12w was associated with better overall survival (adjusted hazard ratio (aHR) 0.46, 95%CI 0.24-0.90), and disease-free survival (aHR 0.48, 95%CI 0.24-0.94), but also with more postoperative respiratory complications (aOR 3.66, 95%CI 1.52-9.59). Other outcomes were comparable between both groups.
Prolonged TTS in patients with histologically proven residual disease after completion of nCRT for esophageal cancer did not have a negative effect on overall and disease-free survival, but patients did have a higher risk for postoperative respiratory complications.
探讨手术时间延长是否会对局部晚期食管癌新辅助放化疗后组织学证实有残留病灶患者的生存、病理结果或术后并发症产生负面影响。
从历史上看,标准手术时间(TTS)是在完成新辅助放化疗后6至8周。手术时间延长的影响日益受到关注,关于生存和手术并发症的结果相互矛盾。可以推测,在完成新辅助放化疗6周后仍有残留病灶的患者中,手术时间延长可能与较差的生存和较高的并发症发生率相关。
对局部晚期食管癌患者进行研究,这些患者在新辅助放化疗6周后经活检证实有残留病灶并接受了手术,根据手术间隔时间(TTS>12周与TTS≤12周)进行分类。本研究的主要结局是总生存期。次要结局包括无病生存期、手术结局、病理结局和术后并发症。采用多变量Cox回归比较生存率,采用逻辑回归比较其他结局,并对年龄、cT、cN、Charlson合并症指数、新辅助放化疗期间体重减轻以及完成新辅助放化疗后的WHO体能状态评分等混杂因素进行校正。
TTS>12周组纳入40例患者,TTS≤12周组纳入127例患者。TTS>12周与更好的总生存期(调整后风险比[aHR]0.46,95%置信区间[CI]0.24-0.90)和无病生存期(aHR 0.48,95%CI 0.24-0.94)相关,但也与更多的术后呼吸并发症相关(调整后比值比[aOR]3.66,95%CI 1.52-9.59)。两组的其他结局相当。
食管癌新辅助放化疗完成后组织学证实有残留病灶的患者,手术时间延长对总生存期和无病生存期没有负面影响,但患者术后呼吸并发症的风险更高。